Photodynamic therapy (PDT) is a cancer treatment that utilizes visible or near-infrared light to activate a light- sensitive drug (photosensitizer, PS) that, in turn, creates reactive singlet oxygen species from ground triplet state oxygen that is present in the tumor. The resulting reactive products induce tissue death. Ideally the reactive species will be produced within only the target volume, leading to damage of the tumor or diseased tissues, while minimizing damage to surrounding normal tissue. Unlike chemotherapy, PDT does not cause systemic toxicities, and unlike radiation therapy it does not cause cumulative damage in the local field. When an external light beam is used to treat superficial surface or intracavitary surface cancers, the effective depth of light penetration and treatment is limited to < 10 mm. For deeply seated tumors or tumors that are more than 10 mm in thickness, intra-tumor light delivery (interstitial PDT, I-PDT) is required to activate the PS.

Public Health Relevance

We aim to develop a novel hardware and software prototype platform that integrates real-time light dosimetry with feedback-enabled Photodynamic Therapy (PDT)-dose calculations to provide I-PDT pre- treatment dosimetry planning and in situ monitoring for animal and clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44CA213654-03
Application #
9789205
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Narayanan, Deepa
Project Start
2017-06-01
Project End
2020-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Simphotek, Inc.
Department
Type
DUNS #
800606860
City
Newark
State
NJ
Country
United States
Zip Code
07103